Since aberrant pathway activity can occur independently of mutations in the corresponding genes, we confirmed that 48.3% of patients with STAD display simultaneous elevated transcriptional activation in the RTK/KRAS and PI3K pathways and 23% in the RTK/KRAS, PI3K, and TP53 pathways (Figures S1C and S1D). The gene discussed is TP53; the disease is gastric adenocarcinoma.